1. Jameson JL, Kasper DL, Fauci AS, Hauser SL, Longo DL, Loscalzo J. Harrison's principles of internal medicine: McGraw-hill education; 2018.

2. Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol 2021; 3(1):e19-e27.

3. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmunity Reviews 2014;13(11):1102-8.

4. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013;52(1):53-61.

5. Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology. 2013;52(10):1809-17.

6. Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmunity Reviews. 2013;12(7):726-40.

7. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheumatic Dis 2007; 66(3):308-12.

8. Smolen JS, Landewé RB, Bijlsma JW, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79(6):685-99.

9. Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids—All-Rounders tackling the versatile players of the immune system. Frontiers Immunol 2019; 10: 1744.

10. Ni YN, Chen G, Sun J, Liang B-M, Liang ZA. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care 2019; 23(1): 99. doi: 10.1186/s13054-019-2395-8.

11. Tang NLS, Chan PKS, Wong CK, To KF, Wu AKL, Sung Y-M, et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clinical chemistry. 2005;51(12):2333-40.

12. Organization WH. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. World Health Organization; 2020.

13. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease‐modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Care Res 2008;59(8):1074-81.

14. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35(3): 387-93.

15. Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmunity Reviews. 2013;12(12):1115-7.

16. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus EF. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the rheumatic diseases. 2020; 79(7):859-66.

17. Gordon AC, Angus DC, Derde LP. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply. New England J Med 2021; 385(12): 1147-9.

18. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England J Med 2021; 384(9):795-807.

19. Selmi C, Ceribelli A, Naguwa SM, Cantarini L, Shoenfeld Y. Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf 2015; 14(3):389-99.

20. Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry. Ann Rheumatic Dis 2021; 80(9): 1137-46.

21. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50(1):124-31.

22. Esalatmanesh K, Jamali R, Jamali A, Jamali B, Nikbakht M. Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis. Rheumatol Int 2012; 32(12):3799-805.

23. Roongta R, Ghosh A. Managing rheumatoid arthritis during COVID-19. Clinical rheumatology. 2020 Nov;39(11):3237-44.

24. Chuo CY, Yau V, Madhavan S, Tsai L, Chia J. Risk of Severe COVID-19 Outcomes Among Patients with Rheumatoid Arthritis in the United States. medRxiv. 2021 Jan 1.

25. Van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016; 34(5 Suppl 101): S40-4.

26. Smolen JS, Aletaha D. Assessment of rheumatoid arthritis activity in clinical trials and clinical practice. Curr Opin Rheumatol 2011; 23(3): 252-8.

27. National Health Commission of China. The guidelines for diagnosis and treatment of novel coronavirus (2019‐nCoV) infected pneumonia (the sixth edition draft) issued by the National Health Commission of China.

28. Wang D, Hu B, Hu C, Zhu F, Xing Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–9.

29. Zhu Y, Zhong J, Dong L. Epidemiology and clinical management of rheumatic autoimmune diseases in the COVID-19 pandemic: A review. Frontiers in Medicine. 2021;8.

30. Pablos JL. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Cells. 2020; 79:1544–9. doi: 10.1136/annrheumdis-2020-218296

31. Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology. 2021; keab250. doi: 10.1093/rheumatology/keab250

32. Vázquez-Díaz M, Freites Nuñez DD, Leon L. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Rheumatol Int 2020; 79: 1393–9. doi: 10.1136/annrheumdis-2020-217984

33. Tiendrébéogo WJS, Kaboré F, Ntsiba H, Montero F. Coronavirus disease 2019. (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Clin Rheumatol. 2020; 40:1593–8. doi: 10.1007/s00296-020-04676-4

34. Ladani AP, Loganathan M, Danve A. Managing rheumatic diseases during COVID-19. Clin Rheumatol 2020;39(11):3245-54.